Brief: Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis
15/12/2025 12:21
Dec 15 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O : VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026 Source text: ID:nPn1J0jnCa Further company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program